Attention-deficit hyperactivity disorder: recent advances in paediatric pharmacotherapy (Q39916663)

15 September 2017

Attention-deficit hyperactivity disorder: recent advances in paediatric pharmacotherapy (English)

1 reference

attention deficit hyperactivity disorder

15 September 2017

0 references

0 references

1 reference

Diane E May

1

1 reference

PubMed ID

20030423

15 September 2017

Christopher J Kratochvil

series ordinal

2

1 reference

15 September 2017

1 January 2010

1 reference

15 September 2017

1 reference

15 September 2017

70

1 reference

15 September 2017

1

1 reference

15 September 2017

15-40

1 reference

https://scigraph.springernature.com/pub.10.2165/11530540-000000000-00000

15 September 2017

0 references

cites work

Practice parameter for the use of stimulant medications in the treatment of children, adolescents, and adults

1 reference

https://api.crossref.org/works/10.2165%2F11530540-000000000-00000

A teacher rating scale for use in drug studies with children

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11530540-000000000-00000

A 13-hour laboratory school study of lisdexamfetamine dimesylate in school-aged children with attention-deficit/hyperactivity disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11530540-000000000-00000

Long-term, open-label extension study of guanfacine extended release in children and adolescents with ADHD.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11530540-000000000-00000

Treatment of ADHD in children with tics: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11530540-000000000-00000

Health care use and costs for children with attention-deficit/hyperactivity disorder: national estimates from the medical expenditure panel survey.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11530540-000000000-00000

A systematic review and economic model of the effectiveness and cost-effectiveness of methylphenidate, dexamfetamine and atomoxetine for the treatment of attention deficit hyperactivity disorder in children and adolescents

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11530540-000000000-00000

Clonidine for attention-deficit/hyperactivity disorder: II. ECG changes and adverse events analysis

21 January 2018

1 reference

12 December 2020

1 reference

12 December 2020

Comparing the efficacy of medications for ADHD using meta-analysis

1 reference

12 December 2020

Effect of comorbid symptoms of oppositional defiant disorder on responses to atomoxetine in children with ADHD: a meta-analysis of controlled clinical trial data

1 reference

12 December 2020

Treatment of attention-deficit/hyperactivity disorder: overview of the evidence

1 reference

12 December 2020

The effect of alpha-2 adrenergic agonists on memory and cognitive flexibility.

1 reference

12 December 2020

Efficacy and safety of dexmethylphenidate extended-release capsules in children with attention-deficit/hyperactivity disorder

1 reference

12 December 2020

Reliability and validity of the SKAMP rating scale in a laboratory school setting

1 reference

12 December 2020

Neurobehavioral effects of racemic threo-methylphenidate and its D and L enantiomers in rats

1 reference

12 December 2020

CYP2D6 metabolizer status and atomoxetine dosing in children and adolescents with ADHD.

1 reference

12 December 2020

Long-term effects of extended-release mixed amphetamine salts treatment of attention- deficit/hyperactivity disorder on growth

1 reference

12 December 2020

Atomoxetine improves patient and family coping in attention deficit/hyperactivity disorder: a randomized, double-blind, placebo-controlled study in Swedish children and adolescents

1 reference

12 December 2020

Clinical practice guideline: treatment of the school-aged child with attention-deficit/hyperactivity disorder

1 reference

12 December 2020

Remission versus response as the goal of therapy in ADHD: a new standard for the field?

1 reference

12 December 2020

A randomized, double-blind, placebo-controlled study of guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder

1 reference

12 December 2020

Effectiveness outcomes in attention-deficit/hyperactivity disorder

1 reference

12 December 2020

National Institute of Mental Health Multimodal Treatment Study of ADHD follow-up: changes in effectiveness and growth after the end of treatment.

1 reference

12 December 2020

Comparison of symptomatic versus functional changes in children and adolescents with ADHD during randomized, double-blind treatment with psychostimulants, atomoxetine, or placebo

1 reference

12 December 2020

A modelled economic evaluation comparing atomoxetine with methylphenidate in the treatment of children with attention-deficit/hyperactivity disorder in Spain

1 reference

12 December 2020

A randomized, double-blind, placebo-controlled, laboratory classroom assessment of methylphenidate transdermal system in children with ADHD.

1 reference

12 December 2020

Outcomes of OROS methylphenidate compared with atomoxetine in children with ADHD: a multicenter, randomized prospective study

1 reference

12 December 2020

Comparative effects of methylphenidate and mixed salts amphetamine on height and weight in children with attention-deficit/hyperactivity disorder

1 reference

12 December 2020

Relative bioavailability of lisdexamfetamine 70-mg capsules in fasted and fed healthy adult volunteers and in solution: a single-dose, crossover pharmacokinetic study

1 reference

12 December 2020

The MTA at 8 Years: Prospective Follow-up of Children Treated for Combined-Type ADHD in a Multisite Study

1 reference

12 December 2020

Pharmacokinetics of methylphenidate transdermal system (MTS): results from a laboratory classroom study

1 reference

12 December 2020

The PedsQL as a patient-reported outcome in children and adolescents with Attention-Deficit/Hyperactivity Disorder: a population-based study

1 reference

12 December 2020

Relapse prevention in pediatric patients with ADHD treated with atomoxetine: a randomized, double-blind, placebo-controlled study

1 reference

12 December 2020

Atomoxetine treatment in children and adolescents with attention-deficit/hyperactivity disorder and comorbid oppositional defiant disorder

1 reference

12 December 2020

Pharmacokinetics of SLI381 (ADDERALL XR), an extended-release formulation of Adderall

1 reference

12 December 2020

CYP2D6 and clinical response to atomoxetine in children and adolescents with ADHD.

1 reference

12 December 2020

Stimulation of alpha2-adrenoceptors suppresses excitatory synaptic transmission in the medial prefrontal cortex of rat.

1 reference

12 December 2020

Adderall produces increased striatal dopamine release and a prolonged time course compared to amphetamine isomers.

1 reference

12 December 2020

Comorbid oppositional defiant disorder and the risk of relapse during 9 months of atomoxetine treatment for attention-deficit/hyperactivity disorder

1 reference

12 December 2020

Dexmethylphenidate extended-release capsules in children with attention-deficit/hyperactivity disorder

1 reference

12 December 2020

Differential effects of the D- and L- isomers of amphetamine on pharmacological MRI BOLD contrast in the rat.

1 reference

12 December 2020

Atomoxetine treatment of ADHD in children with comorbid Tourette syndrome

1 reference

12 December 2020

A randomized, double-blind, crossover study of once-daily dexmethylphenidate in children with attention-deficit hyperactivity disorder: rapid onset of effect

1 reference

12 December 2020

Effects of application to two different skin sites on the pharmacokinetics of transdermal methylphenidate in pediatric patients with attention-deficit/hyperactivity disorder.

1 reference

12 December 2020

Tic exacerbation and precipitation during atomoxetine treatment in two children with attention-deficit hyperactivity disorder

1 reference

12 December 2020

Once-daily multilayer-release methylphenidate in a double-blind, crossover comparison to immediate-release methylphenidate in children with attention-deficit/hyperactivity disorder

1 reference

12 December 2020

Meta-analysis of suicide-related behavior events in patients treated with atomoxetine

1 reference

12 December 2020

Pharmacokinetics of a guanfacine extended-release formulation in children and adolescents with attention-deficit-hyperactivity disorder.

1 reference

12 December 2020

Changes in symptoms and adverse events after discontinuation of atomoxetine in children and adults with attention deficit/hyperactivity disorder: a prospective, placebo-controlled assessment.

1 reference

12 December 2020

Growth in stimulant-naive children with attention-deficit/hyperactivity disorder using cross-sectional and longitudinal approaches.

1 reference

12 December 2020

Abuse liability assessment of atomoxetine in a drug-abusing population

1 reference

12 December 2020

Equivalent effects of stimulant treatment for attention-deficit hyperactivity disorder during childhood and adolescence.

1 reference

12 December 2020

Indication and use of drug products used to treat attention-deficit/hyperactivity disorder: a cross-sectional study with inference on the likelihood of treatment in adulthood

1 reference

12 December 2020

An open trial of guanfacine in the treatment of attention-deficit hyperactivity disorder

1 reference

12 December 2020

Practical management of cutaneous reactions to the methylphenidate transdermal system: recommendations from a dermatology expert panel consensus meeting.

1 reference

12 December 2020

Age of methylphenidate treatment initiation in children with ADHD and later substance abuse: prospective follow-up into adulthood

1 reference

12 December 2020

Atomoxetine for the treatment of attention-deficit/hyperactivity disorder and oppositional defiant disorder

1 reference

12 December 2020

Atomoxetine versus methylphenidate in paediatric outpatients with attention deficit hyperactivity disorder: a randomized, double-blind comparison trial.

1 reference

12 December 2020

Treatment of children with attention-deficit/hyperactivity disorder: results of a randomized, multicenter, double-blind, crossover study of extended-release dexmethylphenidate and D,L-methylphenidate and placebo in a laboratory classroom setting.

1 reference

12 December 2020

l-Amphetamine improves poor sustained attention while d-amphetamine reduces overactivity and impulsiveness as well as improves sustained attention in an animal model of Attention-Deficit/Hyperactivity Disorder (ADHD)

1 reference

12 December 2020

Stimulant treatment in children with attention-deficit/hyperactivity disorder moderates adolescent academic outcome

1 reference

12 December 2020

Guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder: a placebo-controlled trial

1 reference

12 December 2020

Atomoxetine use associated with onset of a motor tic.

1 reference

12 December 2020

Modifiers of long-term school outcomes for children with attention-deficit/hyperactivity disorder: does treatment with stimulant medication make a difference? Results from a population-based study.

1 reference

12 December 2020

1 reference

12 December 2020

The revised Conners' Parent Rating Scale (CPRS-R): factor structure, reliability, and criterion validity

1 reference

12 December 2020

1 reference

12 December 2020

Effects of Stimulant Medication on Growth Rates Across 3 Years in the MTA Follow-up

1 reference

12 December 2020

A dose-ranging study of a methylphenidate transdermal system in children with ADHD.

1 reference

12 December 2020

A randomized, double-blind, placebo-controlled, parallel-group study of methylphenidate transdermal system in pediatric patients with attention-deficit/hyperactivity disorder

1 reference

12 December 2020

A placebo-controlled study of guanfacine in the treatment of children with tic disorders and attention deficit hyperactivity disorder

1 reference

12 December 2020

Patterns and predictors of attention-deficit/hyperactivity disorder persistence into adulthood: results from the national comorbidity survey replication

1 reference

12 December 2020

Transdermal methylphenidate, behavioral, and combined treatment for children with ADHD.

1 reference

12 December 2020

The adolescent outcome of hyperactive children diagnosed by research criteria: I. An 8-year prospective follow-up study

1 reference

12 December 2020

A randomized, double-blind study of continuation treatment for attention-deficit/hyperactivity disorder after 1 year

1 reference

12 December 2020

Pharmacological and therapeutic directions in ADHD: Specificity in the PFC.

1 reference

12 December 2020

Once-daily atomoxetine treatment for children and adolescents with attention deficit hyperactivity disorder: a randomized, placebo-controlled study.

1 reference

12 December 2020

A comparison of morning-only and morning/late afternoon Adderall to morning-only, twice-daily, and three times-daily methylphenidate in children with attention-deficit/hyperactivity disorder

1 reference

12 December 2020

Atomoxetine and osmotically released methylphenidate for the treatment of attention deficit hyperactivity disorder: acute comparison and differential response.

1 reference

12 December 2020

ADHD in Children Onset of Efficacy of Long-Acting Psychostimulants in Pediatric Attention-Deficit/Hyperactivity Disorder

1 reference

12 December 2020

Do stimulants protect against psychiatric disorders in youth with ADHD? A 10-year follow-up study

1 reference

12 December 2020

Prospective follow-up of girls with attention-deficit/hyperactivity disorder into adolescence: Evidence for continuing cross-domain impairment.

1 reference

12 December 2020

Randomised controlled study-efficacy of clonidine versus carbamazepine in children with ADHD.

1 reference

12 December 2020

Treating attention-deficit/hyperactivity disorder with a stimulant transdermal patch: the clinical art.

1 reference

12 December 2020

Bioequivalence of a methylphenidate hydrochloride extended-release preparation: comparison of an intact capsule and an opened capsule sprinkled on applesauce.

1 reference

12 December 2020

Effects of long-term atomoxetine treatment for young children with attention-deficit/hyperactivity disorder

1 reference

12 December 2020

ADHD treatment with once-daily OROS methylphenidate: final results from a long-term open-label study

1 reference

12 December 2020

Safety and tolerability of atomoxetine over 3 to 4 years in children and adolescents with ADHD.

1 reference

12 December 2020

Efficacy and safety of extended-release dexmethylphenidate compared with d,l-methylphenidate and placebo in the treatment of children with attention-deficit/hyperactivity disorder: a 12-hour laboratory classroom study

1 reference

12 December 2020

Long-term effectiveness and safety of lisdexamfetamine dimesylate in school-aged children with attention-deficit/hyperactivity disorder

1 reference

12 December 2020

Differential effects of amphetamine isomers on dopamine release in the rat striatum and nucleus accumbens core

1 reference

12 December 2020

Development of tics in a thirteen-year-old male following atomoxetine use.

1 reference

12 December 2020

Stereoselective effects of methylphenidate on motor hyperactivity in juvenile rats induced by neonatal 6-hydroxydopamine lesioning

1 reference

12 December 2020

Treatment for ADHD: is more complex treatment cost-effective for more complex cases?

1 reference

12 December 2020

Impact of attention-deficit/hyperactivity disorder (ADHD) on prescription dug spending for children and adolescents: increasing relevance of health economic evidence

1 reference

12 December 2020

Atomoxetine treatment for pediatric patients with attention-deficit/hyperactivity disorder with comorbid anxiety disorder.

1 reference

12 December 2020

A four-year follow-up study of the effects of methylphenidate on the behavior and academic achievement of hyperactive children

1 reference

12 December 2020

Practice Parameter for the Assessment and Treatment of Children and Adolescents With Attention-Deficit/Hyperactivity Disorder

1 reference

12 December 2020

Efficacy and safety of atomoxetine for attention-deficit/hyperactivity disorder in children and adolescents-meta-analysis and meta-regression analysis.

1 reference

12 December 2020

Psychometric properties of teacher SKAMP ratings from a community sample

1 reference

12 December 2020

Long-Term Effects of Methylphenidate Transdermal Delivery System Treatment of ADHD on Growth

1 reference

12 December 2020

A meta-analysis of clonidine for symptoms of attention-deficit hyperactivity disorder

1 reference

12 December 2020

Comparative pharmacodynamics and plasma concentrations of d-threo-methylphenidate hydrochloride after single doses of d-threo-methylphenidate hydrochloride and d,l-threo-methylphenidate hydrochloride in a double-blind, placebo-controlled, crossover

1 reference

12 December 2020

Efficacy and tolerability of lisdexamfetamine dimesylate (NRP-104) in children with attention-deficit/hyperactivity disorder: a phase III, multicenter, randomized, double-blind, forced-dose, parallel-group study.

1 reference

12 December 2020

Stimulant therapy and risk for subsequent substance use disorders in male adults with ADHD: a naturalistic controlled 10-year follow-up study

1 reference

12 December 2020

Efficacy and duration of effect of extended-release dexmethylphenidate versus placebo in schoolchildren with attention-deficit/hyperactivity disorder.

1 reference

12 December 2020

Effects of atomoxetine on growth after 2-year treatment among pediatric patients with attention-deficit/hyperactivity disorder

1 reference

12 December 2020

Evolution of the treatment of attention-deficit/hyperactivity disorder in children: a review

1 reference

12 December 2020

Long-acting medications for the hyperkinetic disorders. A note on cost-effectiveness

1 reference

12 December 2020

A modeled economic evaluation comparing atomoxetine with stimulant therapy in the treatment of children with attention-deficit/hyperactivity disorder in the United Kingdom

1 reference

12 December 2020

Long-term atomoxetine treatment in adolescents with attention-deficit/hyperactivity disorder.

1 reference

12 December 2020

Bioavailability of modified-release methylphenidate: influence of high-fat breakfast when administered intact and when capsule content sprinkled on applesauce

1 reference

12 December 2020

Results from 2 proof-of-concept, placebo-controlled studies of atomoxetine in children with attention-deficit/hyperactivity disorder.

1 reference

12 December 2020

Lisdexamfetamine dimesylate and mixed amphetamine salts extended-release in children with ADHD: a double-blind, placebo-controlled, crossover analog classroom study

1 reference

12 December 2020

Abuse liability and safety of oral lisdexamfetamine dimesylate in individuals with a history of stimulant abuse

1 reference

12 December 2020

Effects of atomoxetine on growth in children with attention-deficit/hyperactivity disorder following up to five years of treatment.

1 reference

12 December 2020

Hepatic events associated with atomoxetine treatment for attention-deficit hyperactivity disorder

1 reference

12 December 2020

Efficacy and safety of atomoxetine in adolescents with attention-deficit/hyperactivity disorder and major depression.

1 reference

12 December 2020

Evaluation of the reinforcing effects of atomoxetine in monkeys: comparison to methylphenidate and desipramine

1 reference

12 December 2020

A single-dose, two-way crossover, bioequivalence study of dexmethylphenidate HCl with and without food in healthy subjects

1 reference

12 December 2020

Guanfacine treatment of comorbid attention-deficit hyperactivity disorder and Tourette's syndrome: preliminary clinical experience

1 reference

12 December 2020

Long-term safety and efficacy of guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder

1 reference

12 December 2020

Alpha2A-adrenoceptors strengthen working memory networks by inhibiting cAMP-HCN channel signaling in prefrontal cortex.

1 reference

12 December 2020

Clonidine for attention-deficit/hyperactivity disorder: I. Efficacy and tolerability outcomes

1 reference

12 December 2020

Varying the wear time of the methylphenidate transdermal system in children with attention-deficit/hyperactivity disorder

1 reference

12 December 2020

Psychopharmacological interventions

1 reference

12 December 2020

Abdominal Tics During Atomoxetine Treatment in a Child With ADHD: Evaluation and Differential Diagnosis.

1 reference

12 December 2020

Stimulant treatment over 5 years: effects on growth.

1 reference

12 December 2020

A laboratory school comparison of mixed amphetamine salts extended release (Adderall XR) and atomoxetine (Strattera) in school-aged children with attention deficit/hyperactivity disorder

1 reference

12 December 2020

A comparison of once-daily extended-release methylphenidate formulations in children with attention-deficit/hyperactivity disorder in the laboratory school (the Comacs Study).

1 reference

12 December 2020

Cardiovascular effects of longer-term, high-dose OROS methylphenidate in adolescents with attention deficit hyperactivity disorder.

1 reference

12 December 2020

Childhood predictors of adult attention-deficit/hyperactivity disorder: results from the World Health Organization World Mental Health Survey Initiative

1 reference

12 December 2020

Relative efficacy of long-acting stimulants on children with attention deficit-hyperactivity disorder: a comparison of standard methylphenidate, sustained-release methylphenidate, sustained-release dextroamphetamine, and pemoline

1 reference

12 December 2020

Atomoxetine in the treatment of children and adolescents with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled, dose-response study

1 reference

12 December 2020

Atomoxetine pharmacokinetics in children and adolescents with attention deficit hyperactivity disorder

1 reference

12 December 2020

10.2165/11530540-000000000-00000

Identifiers

DOI

1 reference

PubMed ID

20030423

Dimensions Publication ID

15 September 2017

0 references

1 reference

PubMed ID

20030423